Floatz logo

Dc-Cik

Pancreatic Ductal Adenocarcinoma

University of MalayaCell therapyPhase 2/3Active
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
65/ 100

Competitive context

148 Active assets in the Pancreatic Ductal Adenocarcinoma cohort.

Asset / SponsorPhaseRating
Eloxatin
Jonsson Comprehensive Cancer Center
Phase 4BB
FLUOROURACILUM
Jonsson Comprehensive Cancer Center
Phase 3B
Capecitabine
Shenyang Sunshine Pharmaceutical Co., LTD.
Phase 3B
Cyclophosphamide
Beijing Biotech
Phase 2B
Durvalumab
Jonsson Comprehensive Cancer Center
Phase 2B

View all 50 →

Same molecule, other indications

Dc-Cik is also rated in:

Postoperative ComplicationsDormant
BB
Indicative ·
67 / 100
View asset →
Cytokine-induced Killer CellsDormant
BB
Indicative ·
67 / 100
View asset →
Multiple Drug UseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →